Abstract
The SARS-COV-2-19-associated respiratory involvement is caused by the massive release of inflammatory cytokines ultimately leading to interstitial pneumonia and acute respiratory distress syndrome (ARDS). In the absence of an effective antiviral treatment, a reasonable causal approach could be constituted by the neutralization of these substances. The authors describe the clinical course of a patient with SARS-COV-2-19 interstitial pneumonia treated with the combination of an anti-interleukin 6 (IL-6) agent (tocilizumab) and hemoadsorption (HA). This combination was used to abate the surge of inflammatory mediators leading to the lung damage. Blood levels of IL-6 and C-reactive protein (CRP) were measured before the initiation of the treatment and in the following 3 days. At the end of the treatment, the values of IL-6 and CRP decreased from 1,040 to 415 pg/mL and from 229 to 59 mg/L, respectively. The gas exchanges and the chest imaging rapidly improved, and the patient was extubated 10 days later. The combination of tocilizumab and HA could be valuable in the treatment of SARS-COV-2-19-associated pneumonia and ARDS that are caused by the release of inflammatory mediators.
References
1.
Remuzzi
A
, Remuzzi
G
. COVID-19 and Italy: what next?
Lancet
. 2020
;395
(10231
):1225
–8
. 2.
Li
X
, Geng
M
, Peng
Y
, Meng
L
, Su
S
. Molecular immune pathogenesis and diagnosis of SARS-COV-2 -19
. J Pharm Anal
. 2020
;10
(2
):102
–8
. 3.
Jensen
JA
, Sjastaad
FV
, Griffith
TS
, Badovinac
VP
. Sepsis-induced T cell immunoparalysis: the ins and outs of impaired T cell immunity
. J Immunol
. 2018
;200
:1543
–53
.4.
Wang
T
, Du
Z
, Zhu
F
, Cao
Z
, An
Y
, Gao
Y
, et al. Comorbidities and multi-organ injuries in the treatment of COVID-19
. Lancet
. 2020 Mar 21
;395
(10228
):e52
. 5.
Beutel
G
, Wiesner
O
, Eder
M
, Hafer
C
, Schneider
AS
, Kielstein
JT
, et al. Virus-associated hemophagocytic syndrome as a major contributor to death in patients with 2009 influenza A (H1N1) infection
. Crit Care
. 2011
;15
(2
):R80
. 6.
Kyriazopoulou
E
, Leventogiannis
K
, Norrby-Teglund
A
, Dimopoulos
G
, Pantazi
A
, Orfanos
SE
, et al. Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis
. BMC Med
. 2017
;15
(1
):172
–82
. 7.
Gruda
MC
, Ruggenberg
K-C
, O’Sullivan
P
, Guliashvili
T
, Scheirer
AR
, Golobish
TD
, et al. Broad adsorption of sepsis-related PAMP and DAMP molecules, mycotoxin and cytokines from whole blood using CytoSorb® sorbent porous polymer beads
. PLos One
. 2018 Jan 25
;13
(1
):e0191676
. 8.
Malard
B
, Lambert
C
, Kellum
JA
. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices
. Intensive Care Med Exp
. 2018
;6
(1
):12
–25
. 9.
Brouwer
WP
, Duran
S
, Kuijper
, M
, Ince
C
: Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study
. Crit Care
. 2019
;23
(1
):317
–26
. 10.
Zuccari
S
, Damiani
E
, Domizi
R
, Scorcella
C
, D'Arezzo
M
, Carsetti
A
, et al. Changes in cytokines, haemodynamics and microcirculation in patients with sepsis/septic shock undergoing continuous renal replacement therapy and blood purification with CytoSorb
. Blood Purif
. 2020
;49
(1–2
):107
–13
. 11.
Bottari
G
, Merli
P
, Guzzo
I
, Stoppa
F
, Ruggeri
A
, Di Nardo
M
, et al. Multimodal therapeutic approach of cytokine release syndrome developing in a child given chimeric antigen receptor-modified T cell infusion
. Crit Care Explor
. 2020
;2
(1
):e0071
. 12.
Mehta
P
, McAuley
DF
, Brown
M
, Sanchez
E
, Tattersall
RS
, Manson
JJ
. COVID-19: consider cytokine storm syndromes and immunosuppression
. Lancet
. 2020
;395
(10229
):1033
–4
. 13.
Fardet
L
, Galicier
L
, Lambotte
O
, Marzac
C
, Aumont
C
, Chahwan
D
, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome
. Arthritis Rheumatol
. 2014
;66
(9
):2613
–20
. 14.
Daniels
LB
. Pretenders and contenders: inflammation, C-reactive protein, and interleukin-6
. J Am Heart Assoc
. 2017 Oct 24
;6
(10
):e007490
. 15.
Ronco
C
, Reis
T
, De Rosa
S
. Coronavirus epidemic and extracorporeal therapies in intensive care: si vis pacem para bellum
. Blood Purif
. 2020
;49
(3
):255
–8
.16.
Cao
B
, Wen
D
, Liu
W
, Wag
J
, Fan
G
, Ruan
L
, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe SARS-COV-2-19
. New Engl J Med
. 2020
.17.
Dong
L
, Hu
S
, Gao
J
. Discovering drugs to treat coronavirus disease 2019 (COVID-19)
. DD&T
. 2020
;14
(1
):58
–60
. © 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
